Clinical Trial Update: The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating HMPL-523 for safety, tolerability, PK, and preliminary efficacy in adults with immune thrombocytopenia, which has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• HMPL-523

Snippet

Sponsor: Hutchmed | Conditions: Immune Thrombocytopenia, Blood Platelet Disorder | Phase 1 | Status: WITHDRAWN